Steris (STE)
NYSE:STE
Want to see STE full AI Analyst Report?
STE Stock Chart & Stats
$263.77
$1.96(0.95%)
At close: 4:00 PM EST
$263.77
$1.96(0.95%)
Day’s Range― - ―
52-Week Range$195.14 - $269.44
Previous CloseN/A
Volume53.54K
Average Volume (3M)830.03K
Market Cap
$20.26B
Enterprise Value$22.37B
Total Cash (Recent Filing)$439.60M
Total Debt (Recent Filing)$2.09B
Price to Earnings (P/E)26.0
Beta0.33
Next Earnings
Aug 10, 2026EPS Estimate
2.5Next Dividend Ex-DateN/A
Dividend Yield0.94%
Share Statistics
EPS (TTM)7.95
Shares Outstanding97,602,486
10 Day Avg. Volume860,525
30 Day Avg. Volume830,032
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit8.52
Enterprise Value/Ebitda16.62
Forecast
1Y Price Target
$284.50Price Target Upside7.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)11.15
Revenue Forecast (FY)$6.36B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthA materially lower leverage profile and rising equity provide durable financial flexibility: supports sustained capex, tuck‑in M&A, multi-year buybacks and dividend growth, and increases resilience to macro shocks. Low structural leverage reduces refinancing and interest-rate risks over 2–6 months.
Recurring Consumables And ServicesA business model weighted to consumables, maintenance and outsourced services creates high-repeat revenue and visibility. Installed-equipment affinity products and multi-year service contracts produce predictable cashflows, high customer stickiness, and margin durability versus one-time equipment sales.
Strong Cash Generation / Free Cash FlowConsistent, large free cash flow enables sustained reinvestment and shareholder returns while funding strategic projects. Multi-hundred-million FCF cushions working-capital swings, supports the $1B buyback plan and capex for capacity expansions without materially weakening the balance sheet.
Bears Say
Persistent Tariff Cost ExposureOngoing tariffs and related import costs are a sustained margin headwind; management models $60–65M of annual tariff spend and assumes no refunds. This structural cost pressure reduces margin upside and forces reliance on pricing or productivity to preserve long‑term profitability.
Earnings Volatility And Reporting InconsistenciesHistoric profit swings and inconsistent operating‑measure disclosures complicate forecasting and weaken confidence in margin sustainability. Such volatility makes medium-term planning, guidance credibility and comparability across quarters more difficult for investors and counterparties.
AST/service Softness & Inventory-driven Demand VariabilityDemand variability from med‑tech customers reducing inventories and episodic service softness creates structural cyclicality in parts of revenue. Service and consumable pull-through can be delayed, increasing short-to-medium term revenue and utilization volatility despite a stable installed base.
Steris News
STE FAQ
What was Steris’s price range in the past 12 months?
Steris lowest stock price was $195.14 and its highest was $269.44 in the past 12 months.
What is Steris’s market cap?
Steris’s market cap is $20.26B.
When is Steris’s upcoming earnings report date?
Steris’s upcoming earnings report date is Aug 10, 2026 which is in 57 days.
How were Steris’s earnings last quarter?
Steris released its earnings results on May 11, 2026. The company reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.849 by -$0.019.
Is Steris overvalued?
According to Wall Street analysts Steris’s price is currently Undervalued.
Does Steris pay dividends?
Steris pays a Quarterly dividend of $0.63 which represents an annual dividend yield of 0.94%. See more information on Steris dividends here
What is Steris’s EPS estimate?
Steris’s EPS estimate is 2.5.
How many shares outstanding does Steris have?
Steris has 97,602,486 shares outstanding.
What happened to Steris’s price movement after its last earnings report?
Steris reported an EPS of $2.83 in its last earnings report, missing expectations of $2.849. Following the earnings report the stock price went up 4.459%.
Which hedge fund is a major shareholder of Steris?
Currently, no hedge funds are holding shares in STE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$284.50 (7.86% Upside)
$284.50 (7.86% Upside)
Blogger Sentiment
Bullish
STE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 213.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 43.8%
Last 30 Days ▲ 43.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.46%
12-Months-Change
Fundamentals
Return on Equity
11.05%
Trailing 12-Months
Asset Growth
5.82%
Trailing 12-Months
Company Description
Steris
STERIS plc operates as a global provider, delivering a wide array of products and services crucial for infection prevention and various procedural needs. The company's operations are strategically divided into four primary segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare division offers a comprehensive suite of solutions, encompassing specialized cleaning chemicals and sterility assurance products. It also provides automated systems for endoscope reprocessing and tracking, alongside critical capital equipment for sterile processing departments, such as washers, sterilizers, and accessories for gastrointestinal (GI) procedures. Additionally, this segment furnishes essential operating room equipment, including surgical tables, lighting, and connectivity solutions. Beyond products, the Healthcare division offers extensive support services, which include equipment management, installation, maintenance, upgrades, repairs, and troubleshooting for capital assets. It also delivers preventive maintenance programs, general repair services, and specialized instrument and endoscope repair. Furthermore, the division provides tailored consulting for process improvement and manages outsourced sterile processing services for instruments. The Applied Sterilization Technologies segment specializes in offering outsourced sterilization and testing services. These are provided to manufacturers of medical devices and pharmaceuticals through its expansive network of approximately 50 dedicated contract sterilization and laboratory facilities. In the Life Sciences sector, STERIS focuses on the design, production, and sale of consumable items. These include formulated cleaning chemistries, barrier and sterility assurance products, various sterilizers (both steam and vaporized hydrogen peroxide), and washer disinfectors. This segment also provides equipment installation, maintenance, upgrades, repairs, and troubleshooting, in addition to preventive maintenance programs. Finally, the Dental segment caters to dental practices by supplying a range of hand and powered dental instruments, infection control solutions, personal protective equipment (PPE), and products designed to maintain water quality within dental suites. STERIS's diverse portfolio of products and services reaches a broad clientele, including hospitals, other healthcare institutions, and pharmaceutical manufacturers. Established in 1985, STERIS plc maintains its corporate headquarters in Dublin, Ireland.
STE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all STE earnings summariesSTE Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
STE Stock 12 Month Forecast
Average Price Target
$284.50
▲(7.86% Upside)
Technical Analysis
Ownership Overview
0.29% Insiders
27.51% Mutual Funds
19.82% Other Institutional Investors
24.03% Public Companies and
Individual Investors